A Phase 3 interventional study of Ranolazine and Placebo to match ranolazine in Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 146 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-23.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.
Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 4 in phase 3, and was the 8th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 442 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 47 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
12 studies in Diabetes Mellitus, Type 2 by Gilead Sciences: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 12 studies in Diabetes Mellitus, Type 2 by Gilead Sciences, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 3 in phase 3, and was the 11th registered.
Gilead Sciences’s Diabetes Mellitus, Type 2 studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 12 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening). Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24. Participants are required to maintain their diet and exercise regimen.
Drug: Ranolazine · Drug: Metformin · Drug: Placebo to match metformin · Behavioral: Diet · Behavioral: Exercise
Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening). Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24. Participants are required to maintain their diet and exercise regimen.
Drug: Placebo to match ranolazine · Drug: Metformin · Behavioral: Diet · Behavioral: Exercise
Ranolazine tablet(s) administered orally
Also known as: Ranexa®
Placebo to match ranolazine for the duration of the study
Metformin tablet(s) administered orally once daily
Placebo to match metformin for the duration of the study
Participants are instructed to continue the diet regimen prescribed by their physician.
Participants are instructed to continue the exercise regimen prescribed by their physician.
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
The average (mean) change from baseline in HbA1c at Week 24 was analyzed.
Time frame: Baseline; Week 24
Change From Baseline in Fasting Serum Glucose at Week 24
The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.
Time frame: Baseline; Week 24
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received.
Time frame: Baseline; Week 24
Participants were enrolled (during the Qualifying Period) at a total of 112 study sites in Canada, Europe, Asia, Mexico, South Africa, and the United States. The first participant was screened on 28 June 2012. The last participant observation occurred on 01 October 2013.
| Milestone | Placebo+Metformin | Ranolazine+Metformin |
|---|---|---|
| Started | 222 | 220 |
| Completed | 182 | 185 |
| Not completed | 40 | 35 |
| Withdrew: Adverse event | 5 | 7 |
| Withdrew: Hyperglycemia | 0 | 1 |
| Withdrew: Investigator's discretion | 2 | 2 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Protocol violation | 9 | 5 |
| Withdrew: Subject non-compliance | 14 | 6 |
| Withdrew: Subject withdrew consent | 6 | 11 |
The average (mean) change from baseline in HbA1c at Week 24 was analyzed.
| percent of HbA1c in blood | Placebo+Metformin | Ranolazine+Metformin |
|---|---|---|
| HbA1c at Week 24 | 7.86 ± 1.003 | 7.72 ± 1.069 |
| Change from baseline in HbA1c at Week 24 | -0.20 ± 0.949 | -0.37 ± 0.916 |
The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.
| mg/dL | Placebo+Metformin | Ranolazine+Metformin |
|---|---|---|
| Change From Baseline in Fasting Serum Glucose at Week 24 | -3 ± 44.7 | 3 ± 42.5 |
The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received.
| mg/dL | Placebo+Metformin | Ranolazine+Metformin |
|---|---|---|
| Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24 | -4 ± 54.0 | 7 ± 58.2 |
Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo+Metformin | — | 2/222 (0.9%) | 14/222 (6.3%) |
| Ranolazine+Metformin | — | 3/220 (1.4%) | 18/220 (8.2%) |
| Event | Placebo+Metformin | Ranolazine+Metformin |
|---|---|---|
| Impaired gastric emptyingGastrointestinal disorders | 0/222 | 1/220 |
| VomitingGastrointestinal disorders | 0/222 | 1/220 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/222 | 1/220 |
| Metabolic acidosisMetabolism and nutrition disorders | 0/222 | 1/220 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 1/222 | 1/220 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/222 | 1/220 |
| Coronary artery diseaseCardiac disorders | 1/222 | 0/220 |
| Myocardial infarctionCardiac disorders | 1/222 | 0/220 |
| Event | Placebo+Metformin | Ranolazine+Metformin |
|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 14/222 | 18/220 |
Safety Analysis Set: randomized participants who received at least one dose of study treatment.
| Age, Continuous(years) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| Mean | 56 ± 8.9 | 56 ± 9.3 | 56 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| Female | 98 | 121 | 219 |
| Male | 124 | 99 | 223 |
| Ethnicity (NIH/OMB)(Participants) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| Hispanic or Latino | 53 | 37 | 90 |
| Not Hispanic or Latino | 166 | 181 | 347 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race/Ethnicity, Customized(participants) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 52 | 54 | 106 |
| Black or African American | 8 | 11 | 19 |
| White | 160 | 153 | 313 |
| Other | 0 | 2 | 2 |
| Region of Enrollment(participants) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| United States | 82 | 67 | 149 |
| Hungary | 8 | 8 | 16 |
| Czech Republic | 0 | 1 | 1 |
| Mexico | 6 | 4 | 10 |
| Canada | 1 | 3 | 4 |
| Poland | 0 | 5 | 5 |
| Ukraine | 35 | 29 | 64 |
| South Africa | 7 | 4 | 11 |
| Israel | 2 | 1 | 3 |
| Russian Federation | 37 | 49 | 86 |
| India | 44 | 49 | 93 |
| Body Mass Index (BMI)(kg/m^2) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| Mean | 31.2 ± 4.46 | 31.6 ± 4.95 | 31.4 ± 4.71 |
| Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| Mean | 90.8 ± 20.01 | 89.9 ± 21.82 | 90.4 ± 20.91 |
| Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood) | Placebo+Metformin | Ranolazine+Metformin | Total |
|---|---|---|---|
| Mean | 8.09 ± 0.729 | 8.10 ± 0.692 | 8.09 ± 0.710 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 146 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2012, a primary completion of Sep 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine